AU2009248041B2 - Long-acting Y2 and/or Y4 receptor agonists - Google Patents

Long-acting Y2 and/or Y4 receptor agonists Download PDF

Info

Publication number
AU2009248041B2
AU2009248041B2 AU2009248041A AU2009248041A AU2009248041B2 AU 2009248041 B2 AU2009248041 B2 AU 2009248041B2 AU 2009248041 A AU2009248041 A AU 2009248041A AU 2009248041 A AU2009248041 A AU 2009248041A AU 2009248041 B2 AU2009248041 B2 AU 2009248041B2
Authority
AU
Australia
Prior art keywords
ethoxy
seq
xaa
acid
acetylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009248041A
Other languages
English (en)
Other versions
AU2009248041A1 (en
Inventor
Rasmus Jorgensen
Sanne Moller Knudsen
Jacob Kofoed
Soren Ostergaard
Jane Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2009248041A1 publication Critical patent/AU2009248041A1/en
Application granted granted Critical
Publication of AU2009248041B2 publication Critical patent/AU2009248041B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009248041A 2008-05-16 2009-05-18 Long-acting Y2 and/or Y4 receptor agonists Ceased AU2009248041B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08156360 2008-05-16
EP08156360.3 2008-05-16
EP09154461 2009-03-05
EP09154461.9 2009-03-05
PCT/EP2009/055989 WO2009138511A1 (en) 2008-05-16 2009-05-18 Long-acting y2 and/or y4 receptor agonists

Publications (2)

Publication Number Publication Date
AU2009248041A1 AU2009248041A1 (en) 2009-11-19
AU2009248041B2 true AU2009248041B2 (en) 2013-10-03

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009248041A Ceased AU2009248041B2 (en) 2008-05-16 2009-05-18 Long-acting Y2 and/or Y4 receptor agonists

Country Status (12)

Country Link
US (1) US20110275559A1 (enExample)
EP (1) EP2279204A1 (enExample)
JP (1) JP2011520847A (enExample)
KR (1) KR20110017874A (enExample)
CN (1) CN102027007A (enExample)
AU (1) AU2009248041B2 (enExample)
BR (1) BRPI0912615A2 (enExample)
CA (1) CA2723855A1 (enExample)
IL (1) IL208836A0 (enExample)
MX (1) MX2010011845A (enExample)
RU (1) RU2504550C2 (enExample)
WO (1) WO2009138511A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450374B9 (en) 2009-07-02 2016-11-23 Takeda Pharmaceutical Company Limited Peptide and use thereof
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
EP2498800A1 (en) * 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2012006566A2 (en) 2010-07-09 2012-01-12 Amylin Pharmaceuticals, Inc. Microcrystalline y receptor agonists
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
WO2015071355A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
ES2732015T3 (es) * 2013-11-15 2019-11-20 Novo Nordisk As Compuestos de PYY selectivos y sus usos
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
EP3094391B1 (en) 2014-01-17 2024-11-20 Repligen Corporation Sterilizing chromatography columns
CN114805527A (zh) * 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
MX392572B (es) * 2015-06-12 2025-03-24 Novo Nordisk As Compuestos del péptido yy (pyy) selectivos y sus usos.
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
CA3175725A1 (en) * 2020-04-17 2021-10-21 William Blackwell Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use
JP2024516395A (ja) 2021-04-27 2024-04-15 アードバーク・セラピューティクス・インコーポレイテッド 苦味受容体アゴニストおよび腸シグナル伝達化合物の組み合わせ

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027978A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005089786A2 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
WO2006005667A2 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123293A3 (en) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
CN101222942A (zh) * 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027978A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005089786A2 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
WO2006005667A2 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety

Also Published As

Publication number Publication date
RU2504550C2 (ru) 2014-01-20
EP2279204A1 (en) 2011-02-02
BRPI0912615A2 (pt) 2016-01-26
MX2010011845A (es) 2010-11-22
AU2009248041A1 (en) 2009-11-19
CA2723855A1 (en) 2009-11-19
KR20110017874A (ko) 2011-02-22
IL208836A0 (en) 2011-01-31
WO2009138511A1 (en) 2009-11-19
US20110275559A1 (en) 2011-11-10
CN102027007A (zh) 2011-04-20
RU2010149474A (ru) 2012-06-27
JP2011520847A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
AU2009248041A1 (en) Long-acting Y2 and/or Y4 receptor agonists
AU2004273573B2 (en) Albumin-binding derivatives of therapeutic peptides
JP4585037B2 (ja) アシル化ｇｌｐ−１化合物
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
CN102918055B (zh) 新的胰高血糖素类似物
ES2532116T3 (es) Péptidos derivados con A-B-C-D y sus usos terapéuticos
WO2011033068A1 (en) Long-acting y2 receptor agonists
WO2009030774A1 (en) Truncated glp-1 derivatives and their therapeutical use
JP2007537142A (ja) アルブミン様物質に結合した新規のｇｌｐ−１類似物
CN102933598A (zh) 新型胰高血糖素类似物
JP2007204491A (ja) グルカゴン様ペプチド−２アナログ
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
JP2008545644A (ja) 新規ポリ（エチレングリコール）誘導体とタンパク質へのそのカップリング方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired